New adult ADHD drug receives FDA approval

Apr 24, 2008

The U.S. Food and Drug Administration has approved the first prodrug designed for once-daily treatment of adults with ADHD.

Although ADHD -- attention deficit-hyperactivity disorder -- is often thought of as a childhood malady, it's estimated 4.4 percent of U.S. adults ages 18-to-44 suffer from it. The new drug, Vyvanse, has been marketed in the United States since July 2007 for the treatment of ADHD in children 6-12 years of age.

The manufacturer, Shire PLC, a British-headquartered specialty biopharmaceutical company, said Vyvanse is the only once-daily prodrug stimulant approved to treat adults with ADHD. A prodrug is a medication designed to be inactive until it interacts with enzymes in the stomach, thereby making it difficult to be abused, a Shire spokesman said.

In a clinical study with adults, Vyvanse was shown to significantly improve ADHD symptoms, such as an inability to focus attention, hyperactivity and impulsivity, within the first week of use, Shire officials said.

The company said Vyvanse is now available in dosage strengths of 30 mg, 50 mg and 70 mg. Additional dosage strengths of 20 mg, 40 mg and 60 mg are expected to become available later this year.

Copyright 2008 by United Press International

Explore further: FDA approves new drug for rare genetic disease

add to favorites email to friend print save as pdf

Related Stories

Coming soon: Genetically edited fruit?

32 minutes ago

Recent advances that allow the precise editing of genomes now raise the possibility that fruit and other crops might be genetically improved without the need to introduce foreign genes, according to researchers writing in ...

Image: Fire danger extreme in British Columbia, Canada

43 minutes ago

In parts of British Columbia, Canada, the Canadian Wildfire Information System's (CWIS) interactive map shows extreme wildfire danger. The area targeted on the map is the area where these wildfires are showing ...

Image: Smoke from Russian fires over Arctic Sea

46 minutes ago

Numerous wildfires have dotted the Russian landscape this past summer fire season. Although not quite as the adage says, although still true, where there's fire there's smoke. The smoke in this image has ...

Bat wing practice maximises flight efficiency

1 hour ago

Australian bats developed a high-speed flying technology some 50 million years before aircraft engineers, according to Department of Parks and Wildlife zoologist Norm McKenzie.

Recommended for you

Boxed warnings are common in novel therapeutics

22 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

23 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0